Malignant astrocytic gliomas such as glioblastoma are the most common and lethal
intracranial tumors. These cancers exhibit a relentless malignant progression characterized by …

Glioblastoma is both the most common and lethal primary malignant brain tumor. Extensive
multiplatform genomic characterization has provided a higher-resolution picture of the …

Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …

Diverse genetic, epigenetic, and developmental programs drive glioblastoma, an incurable
and poorly understood tumor, but their precise characterization remains challenging. Here, …

Glioblastoma (GBM) is a highly lethal brain tumour presenting as one of two subtypes with
distinct clinical histories and molecular profiles. The primary GBM subtype presents acutely as …

Targeted therapies that inhibit receptor tyrosine kinases (RTKs) and the downstream
phosphatidylinositol 3-kinase (PI3K) signaling pathway have shown promising anticancer activity, …

Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses 1 , 2 and can function as …

The p16 INK4a tumour suppressor accumulates in many tissues as a function of advancing
age 1 , 2 , 3 . p16 INK4a is an effector of senescence 4 , 5 and a potent inhibitor of the …

Brain metastases are associated with a dismal prognosis. Whether brain metastases harbor
distinct genetic alterations beyond those observed in primary tumors is unknown. We …

A high tumour mutational burden (hypermutation) is observed in some gliomas 1 , 2 , 3 , 4 –
5 ; however, the mechanisms by which hypermutation develops and whether it predicts the …